Dtsch Med Wochenschr 2014; 139(06): 251-254
DOI: 10.1055/s-0033-1359994
Intensivmedizin | Commentary
Intensivmedizin, Pneumonie
© Georg Thieme Verlag KG Stuttgart · New York

Ventilator-assoziierte Pneumonie

Ventilator-associated pneumonia
B. Klapdor
1   Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, EVK Herne und Augusta-Kranken-Anstalt Bochum
,
S. Ewig
1   Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, EVK Herne und Augusta-Kranken-Anstalt Bochum
› Author Affiliations
Further Information

Publication History

Publication Date:
28 January 2014 (online)

    Permissions and Reprints

Schlüsselwörter

Ventilator-assoziierte Pneumonie - antimikrobielle Therapie - multiresistente Erreger - MDR - gramnegative Bakterien - Methicillin-resistenter Staphylococcus aureus

Keywords

ventilator-associated pneumonia - antimicrobial therapy - multidrug-resistant pathogens - MDR - gram-negative bacteria - Methicillin-resistant Staphylococcus aureus
 

  • Literatur

  • 1 Berton DC, Kalil AC, Teixeira PJZ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. . Cochrane Database Syst Rev 2012; 1 CD006482
    Google Scholar
  • 2 Blot S, Koulenti D, Dimopoulos G et al. and the EU-VAP Study Investigators. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Crit Care Med 2013; Oct 23. [Epub ahead of print]
    Google Scholar
  • 3 Capellier G, Mockly H, Charpentier C et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS ONE 2012; 7: e41290
    CrossrefGoogle Scholar
  • 4 Craven DE, Lei Y, Ruthazer R et al. Incidence and outcomes of ventilator-associated tracheobronchitis and pneumonia. Am J Med 2013; 126: 542-549
    CrossrefGoogle Scholar
  • 5 Dalfino L, Puntillo F, Mosca A et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012; 54: 1720-1726
    CrossrefGoogle Scholar
  • 6 Dalhoff K, Abele-Horn M, Andreas S et al. Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie. Pneumologie 2012; 66: 707-765
    Article in Thieme ConnectGoogle Scholar
  • 7 Durante-Mangoni E, Signoriello G, Andini R et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57: 349-358
    CrossrefGoogle Scholar
  • 8 Ewig S, Torres A, El-Ebiary M et al. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. Am J Respir Crit Care Med 1999; 159: 188-198
    CrossrefPubMedGoogle Scholar
  • 9 Florescu DF, Qiu F, McCartan MA et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54: 670-680
    CrossrefGoogle Scholar
  • 10 Hill DM, Schroeppel TJ, Magnotti LJ et al. Methicillin-resistant Staphylococcus aureus in early ventilator-associated pneumonia: cause for concern?. Surg Infect 2013; Oct 11. [Epub ahead of print]
    Google Scholar
  • 11 Lu Q, Luo R, Bodin L et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012; 117: 1335-1347
    CrossrefGoogle Scholar
  • 12 Martin-Loeches I, Deja M, Koulenti D et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intens Care Med 2013; 39: 672-681
    CrossrefGoogle Scholar
  • 13 Melsen WG, Rovers MM, Groenwold RHH et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013; 13: 665-671
    CrossrefGoogle Scholar
  • 14 O’Horo JC, Thompson D, Safdar N. Is the gram stain useful in the microbiologic diagnosis of VAP? A meta-analysis. Clin Infect Dis 2012; 55: 551-561
    CrossrefGoogle Scholar
  • 15 Papazian L, Roch A, Charles PE et al. STATIN-VAP Study Group. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 2013; 310: 1692-1700
    CrossrefGoogle Scholar
  • 16 Ranzani OT, Ferrer M, Esperatti M et al. Association between systemic corticosteroids and outcomes of intensive care unit-acquired pneumonia. Crit Care Med 2012; 40: 2552-2561
    CrossrefGoogle Scholar
  • 17 Restrepo MI, Peterson J, Fernandez JF et al. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 2013; 58: 1220-1225
    CrossrefGoogle Scholar
  • 18 Stevens JP, Kachniarz B, Wright SB et al. When policy gets it right: variability in U.S. hospitals’ diagnosis of ventilator-associated pneumonia. Crit Care Med 2013; Oct 18. [Epub ahead of print]
    Google Scholar
  • 19 Stocker DH, Kern WV. Colistin. Internist 2013; 54: 936-944
    CrossrefGoogle Scholar
  • 20 Wunderink RG, Niederman MS, Kollef MH et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54: 621-629
    CrossrefGoogle Scholar